Google
HAE 株価分析 — HAEMONETICS CORPORATION (Healthcare >> Medical Devices)
HAE に関するよくある質問
HAEのPER（株価収益率）は？
HAEMONETICS CORPORATION（HAE）は現在PER 33.66倍で取引されています。
HAEのROE（自己資本利益率）は？
HAEMONETICS CORPORATIONのROEは12.22%です。
HAEの配当利回りは？
HAEMONETICS CORPORATIONの配当利回りは0.00%です。
HAEの品質スコア（Quality Score）は？
当社のAIはHAEの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
HAEは今が買い時ですか？
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
HAEはどのセクターに属しますか？
HAEMONETICS CORPORATIONはHealthcare >> Medical Devicesセクターに分類されます（NYSE市場）
HAE AI Analysis Summary
Our AI summary for HAE: HAEMONETICS CORPORATION (NYSE), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 33.66, ROE of 12.22%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 85.54
Price
0.72
(0.85%)
Day Change
|
|
|---|
HAE, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROEの伸びが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
1734
|
| Magic Formula Rank by ROE |
1734
|
| Magic Formula Rank by ROIC |
1777
|
| Price | 85.54 |
| PBV / Sector |
4.97 / -101.57
|
| Earning Per Share | 2.05 |
| PE / Sector |
33.66 / 31.23
|
| PEG or PE/Growth / Sector |
1.45 / 0.40
|
| Average 1M Daily Value |
47.72 M
GREAT
|
| Average 1W Daily Value |
64.27 M
|
| Timing Factors |
|
85% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
62% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:56 |
| Symbol | HAE |
| Name | HAEMONETICS CORPORATION |
| Sector | Healthcare >> Medical Devices |
| Market | NYSE |
| Listed Shares | 45.45 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3,954.00 / 20,104.97 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 125 Summer Street, Boston, MA, United States, 02110
Phone: 781 848 7100
Website: https://www.haemonetics.com
Employees: 3,009
Sector: Healthcare >> Medical Devices
Description: Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
